Everything you need to know about TMS for Parkinson's Disease: Addressing Motor Symptoms and Mood — how it works, what it costs, and how to find a provider who actually knows what they're doing.
TMS vs. Medication: A Side-by-Side Guide
Free PDF — compare effectiveness, side effects, cost, and timelines so you can choose with confidence.
Parkinson’s disease affects approximately 1 million Americans and 10 million people worldwide. While dopamine replacement therapies (levodopa, dopamine agonists) remain the cornerstone of treatment, many patients experience persistent symptoms despite optimal medication management. Transcranial magnetic stimulation offers a non-invasive approach that may complement pharmacotherapy by directly modulating the motor circuits that degenerate in Parkinson’s.
What You’ll Learn
- How Parkinson’s disrupts the balance between excitatory and inhibitory motor pathways
- Why the primary motor cortex and supplementary motor area are key TMS targets
- What research shows about TMS for motor symptoms, gait, and freezing of gait
- What is known about TMS for Parkinson’s depression
- Practical considerations for patients with Parkinson’s seeking TMS
Understanding Parkinson’s Motor Circuitry
Parkinson’s disease involves the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, disrupting the basal ganglia circuits that coordinate movement. This dysfunction creates an imbalance between:
- Excitatory pathways from the motor cortex through the basal ganglia to thalamus and back to cortex
- Inhibitory pathways that normally suppress unwanted movements
The net effect is excessive cortical excitability and abnormal patterns of motor cortex activation. Patients experience:
- Bradykinesia (slowness of movement)
- Rigidity (stiffness and resistance to passive movement)
- Resting tremor (rhythmic shaking that subsides during voluntary movement)
- Postural instability (balance problems)
Beyond motor symptoms, many Parkinson’s patients also develop Parkinson’s disease depression, which affects up to 40% of patients and is often refractory to standard antidepressants.
How TMS Targets Motor Symptoms
Unlike TMS for depression, which targets the prefrontal cortex, Parkinson’s motor protocols focus on the primary motor cortex and, in some cases, the premotor cortex and supplementary motor area (SMA).
The primary motor cortex (M1) generates the electrical signals that travel down the corticospinal tract to muscles. By modulating M1 excitability, TMS is hypothesized to:
- Reduce pathologically elevated cortical excitability
- Restore more normal patterns of motor cortex activation
- Improve the brain’s responsiveness to remaining dopaminergic signaling
Low-frequency TMS (1 Hz) over the motor cortex is an inhibitory protocol that has been studied for motor symptoms and may reduce the excessive excitability that characterizes Parkinsonian motor cortex activity.
High-frequency TMS (5-25 Hz) over the SMA and premotor cortex has also been studied, including for gait and freezing of gait, with mixed results.
Evidence for Motor Symptom Improvement
Meta-analyses of randomized trials (for example, Chou et al., JAMA Neurology, 2015) have found that rTMS can modestly improve motor scores on the Unified Parkinson’s Disease Rating Scale (UPDRS Part III) compared with sham, with the clearest signal from high-frequency stimulation of the motor cortex. Findings vary across studies, effects on tremor are inconsistent, and effects are modest. Whether benefits can be sustained long term with maintenance sessions is not well established.
TMS for Parkinson’s Depression
Depression in Parkinson’s presents unique challenges. It shares features with both primary mood disorders and secondary depression related to the neurobiological changes of Parkinson’s. Standard antidepressants may interact with dopaminergic medications or worsen motor symptoms.
TMS targeting the left dorsolateral prefrontal cortex (DLPFC) has been studied for Parkinson’s depression in several randomized trials, with meta-analyses suggesting benefit over sham, although study quality varies.
In the trials to date, TMS for Parkinson’s depression has not been reported to worsen motor symptoms, a concern that has limited the use of some medications in this population.
Gait and Freezing of Gait
Freezing of gait (FOG), the sudden inability to initiate or continue walking despite intact leg function, is one of the most disabling and treatment-resistant features of Parkinson’s. FOG often leads to falls and loss of independence.
Repetitive TMS (rTMS) over the supplementary motor area (SMA) has been studied for FOG with encouraging but preliminary results. The SMA is critical for internally-generated motor sequences, and its function is particularly impaired in patients with freezing.
Small sham-controlled studies of high-frequency SMA stimulation have reported reduced freezing and improved gait in some patients, but the trials are small and the protocols and results are not consistent.
Combined Motor and Mood Treatment
An emerging approach involves simultaneous or sequential stimulation of both motor cortex and DLPFC targets, addressing motor symptoms and depression concurrently. This comprehensive approach may be particularly beneficial for patients with significant impairment in both domains.
Dual-target protocols are investigational, and there is little controlled evidence for them so far.
Treatment Parameters
TMS for Parkinson’s in research and off-label settings has involved protocols such as:
- Motor threshold determination using standard protocols
- Motor cortex targeting with neuronavigation or EMG-guided localization
- Low-frequency (1 Hz) stimulation over M1 for motor symptoms
- High-frequency stimulation over SMA for gait dysfunction
- DLPFC stimulation (if treating depression) at 10 Hz or theta burst
- Multiple sessions (typically 10-20) over 2-4 weeks
- Maintenance sessions as needed to sustain benefits
Who Is a Good Candidate?
Patients most likely to benefit from TMS for Parkinson’s include those with:
- Responsive motor symptoms that fluctuate with levodopa dosing
- Depression that has not responded to standard treatments
- Freezing of gait refractory to medication optimization
- Realistic expectations about modest, symptomatic rather than curative benefits
- Absence of significant cognitive impairment that might limit cooperation with treatment
The Current Landscape
While TMS for Parkinson’s is not FDA-cleared in the United States, it is increasingly offered at academic movement disorders centers. Patients should seek treatment from centers with experience in both TMS and Parkinson’s disease to ensure appropriate patient selection and protocol optimization.
As the evidence base grows, TMS may become a standard adjunctive treatment for selected Parkinson’s patients, possibly offering benefit when combined with optimal dopaminergic therapy.
Frequently Asked Questions
Is TMS FDA-cleared for Parkinson's disease?
No. TMS for Parkinson's is not FDA-cleared in the United States. It is increasingly offered at academic movement disorders centers but remains an off-label treatment. Patients should seek treatment from centers with experience in both TMS and Parkinson's disease.
What symptoms of Parkinson's can TMS help with?
TMS has been studied for motor symptoms, Parkinson's-related depression, and freezing of gait. Motor benefits in trials have been modest, effects on tremor are inconsistent, and evidence for freezing of gait is preliminary.
Can TMS worsen Parkinson's motor symptoms?
In trials to date, TMS for Parkinson's depression has not been reported to worsen motor symptoms. Proper motor threshold determination is especially important in Parkinson's patients since corticospinal tract dysfunction may affect threshold values. Treatment should be administered by experienced providers.
Ready to Explore Your TMS Options?
Browse verified TMS providers, read real reviews, and find the right treatment for your situation.
If you have Parkinson’s disease and are experiencing persistent motor symptoms or depression despite optimal medication management, discuss TMS with your movement disorders neurologist to determine whether you may be a candidate.
Related reading
- TMS for Multiple Sclerosis: Addressing Fatigue, Depression, and Cognitive Impairment
- What TMS Actually Feels Like: A Session-by-Session Guide
- How to Prepare for Your First TMS Session
- Preparing for Your First TMS Session: A Practical Walkthrough
- Take the TMS candidacy quiz
- Find a TMS clinic near you
